- Home
- ANL vs BTAI Comparison
ANL vs BTAI Comparison
Compare ANL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | BTAI |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 49.2M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ANL | BTAI |
|---|---|---|
| Price | $1.05 | $2.10 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 12.5K | ★ 658.3K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $544.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $1.17 |
| 52 Week High | $2.99 | $9.26 |
Technical Indicators
Market Signals| Indicator | ANL | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 23.81 | 51.76 |
| Support Level | $1.32 | $1.82 |
| Resistance Level | $1.59 | $2.33 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 1.69 | 62.87 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.